Annual report
4361.TEDINET S100XLSD
Period2024-12-01 → 2025-11-30
Filed2026-02-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.8bn | 2024-12-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥8.9bn | 2023-12-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥8.6bn | 2022-12-01 → 2023-11-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2020-12-01 → 2021-11-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥427m | 2024-12-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥378m | 2023-12-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥405m | 2024-12-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥390m | 2023-12-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥345m | 2022-12-01 → 2023-11-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥386m | 2020-12-01 → 2021-11-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥404m | 2024-12-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥433m | 2023-12-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥256m | 2022-12-01 → 2023-11-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥281m | 2020-12-01 → 2021-11-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥8.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2023-11-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.3bn | at 2022-11-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.9bn | at 2021-11-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥3.1bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.6bn | at 2023-11-30v | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.3bn | at 2021-11-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥745m | at 2024-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2023-11-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥911m | at 2022-11-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.3bn | at 2021-11-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥830m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥143m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥470m | 2022-12-01 → 2023-11-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥21m | 2021-12-01 → 2022-11-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥785m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥739m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥305m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥370m | 2022-12-01 → 2023-11-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥243m | 2021-12-01 → 2022-11-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥246m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥360m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥139m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21m | 2022-12-01 → 2023-11-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥162m | 2021-12-01 → 2022-11-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥119m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥245.11 | 2024-12-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.22 | 2023-12-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.88 | 2022-12-01 → 2023-11-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥230.99 | 2020-12-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,574.02 | at 2025-11-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,367.69 | at 2024-11-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,167.14 | at 2023-11-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,980.62 | at 2022-11-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,850.07 | at 2021-11-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.3% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.8% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-11-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2021-11-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.9% | 2024-12-01 → 2025-11-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2023-12-01 → 2024-11-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2022-12-01 → 2023-11-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2021-12-01 → 2022-11-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-12-01 → 2021-11-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 160 | at 2025-11-30 | Cons. | Number of employees |
| Employees | 171 | at 2024-11-30 | Cons. | Number of employees |
| Employees | 166 | at 2023-11-30v | Cons. | Number of employees |
| Employees | 171 | at 2022-11-30v | Cons. | Number of employees |
| Employees | 165 | at 2021-11-30d | Cons. | Number of employees |
| Revenue | ¥8.6bn | 2024-12-01 → 2025-11-30 | Standalone | Net sales |
| Revenue | ¥8.7bn | 2023-12-01 → 2024-11-30 | Standalone | Net sales |
| Revenue | ¥8.4bn | 2022-12-01 → 2023-11-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.2bn | 2021-12-01 → 2022-11-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.7bn | 2020-12-01 → 2021-11-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥376m | 2024-12-01 → 2025-11-30 | Standalone | Operating income |
| Operating income | ¥362m | 2023-12-01 → 2024-11-30 | Standalone | Operating income |
| Ordinary income | ¥379m | 2024-12-01 → 2025-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥376m | 2023-12-01 → 2024-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥333m | 2022-12-01 → 2023-11-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥262m | 2021-12-01 → 2022-11-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥329m | 2020-12-01 → 2021-11-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥378m | 2024-12-01 → 2025-11-30 | Standalone | Income before income taxes |
| Profit before tax | ¥418m | 2023-12-01 → 2024-11-30 | Standalone | Income before income taxes |
| Net income | ¥277m | 2024-12-01 → 2025-11-30 | Standalone | Profit loss |
| Net income | ¥324m | 2023-12-01 → 2024-11-30 | Standalone | Profit loss |
| Net income | ¥246m | 2022-12-01 → 2023-11-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥185m | 2021-12-01 → 2022-11-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥242m | 2020-12-01 → 2021-11-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.6bn | at 2025-11-30 | Standalone | Assets |
| Total assets | ¥8.3bn | at 2024-11-30 | Standalone | Assets |
| Total assets | ¥8.1bn | at 2023-11-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.2bn | at 2022-11-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.8bn | at 2021-11-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Standalone | Liabilities |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Standalone | Liabilities |
| Net assets / equity | ¥2.9bn | at 2025-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.7bn | at 2024-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.5bn | at 2023-11-30v | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2022-11-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.1bn | at 2021-11-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥968m | at 2025-11-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥506m | at 2024-11-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥227.22 | 2024-12-01 → 2025-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥265.81 | 2023-12-01 → 2024-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.87 | 2022-12-01 → 2023-11-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.85 | 2021-12-01 → 2022-11-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥198.64 | 2020-12-01 → 2021-11-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥60 | 2024-12-01 → 2025-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-12-01 → 2024-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-12-01 → 2023-11-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-12-01 → 2022-11-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-12-01 → 2021-11-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,378.89 | at 2025-11-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,203.77 | at 2024-11-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,015.67 | at 2023-11-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,847.66 | at 2022-11-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,758.24 | at 2021-11-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 33.6% | at 2025-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2023-11-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2022-11-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2021-11-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.9% | 2024-12-01 → 2025-11-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2023-12-01 → 2024-11-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2022-12-01 → 2023-11-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-12-01 → 2022-11-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.9% | 2020-12-01 → 2021-11-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,220,000 | at 2025-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2024-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2023-11-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2022-11-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2021-11-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 155 | at 2025-11-30 | Standalone | Number of employees |
| Employees | 165 | at 2024-11-30 | Standalone | Number of employees |
| Employees | 160 | at 2023-11-30v | Standalone | Number of employees |
| Employees | 166 | at 2022-11-30v | Standalone | Number of employees |
| Employees | 159 | at 2021-11-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | capex | 2024-12-01 → 2025-11-30 | ¥698m |
| Pharmaceutical Productsreportable segment | depreciation | 2024-12-01 → 2025-11-30 | ¥427m |
| Pharmaceutical Productsreportable segment | employees | at 2025-11-30 | 159 pure |
| Pharmaceutical Productsreportable segment | revenue | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Pharmaceutical Productsreportable segment | revenue external | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Pharmaceutical Productsreportable segment | segment assets | at 2025-11-30 | ¥8.8bn |
| Pharmaceutical Productsreportable segment | segment profit | 2024-12-01 → 2025-11-30 | ¥396m |
| Real Estate Leasingreportable segment | employees | at 2025-11-30 | 1 pure |
| Real Estate Leasingreportable segment | revenue | 2024-12-01 → 2025-11-30 | ¥38m |
| Real Estate Leasingreportable segment | revenue external | 2024-12-01 → 2025-11-30 | ¥38m |
| Real Estate Leasingreportable segment | segment assets | at 2025-11-30 | ¥71m |
| Real Estate Leasingreportable segment | segment profit | 2024-12-01 → 2025-11-30 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-12-01 → 2025-11-30 | ¥698m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-12-01 → 2025-11-30 | ¥427m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-12-01 → 2025-11-30 | ¥427m |
| Pharmaceutical Productsreportable segment | capex | 2023-12-01 → 2024-11-30 | ¥344m |
| Pharmaceutical Productsreportable segment | depreciation | 2023-12-01 → 2024-11-30 | ¥404m |
| Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Pharmaceutical Productsreportable segment | segment assets | at 2024-11-30 | ¥8.5bn |
| Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-11-30 | ¥347m |
| Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-11-30 | ¥38m |
| Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-11-30 | ¥38m |
| Real Estate Leasingreportable segment | segment assets | at 2024-11-30 | ¥71m |
| Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-11-30 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-12-01 → 2024-11-30 | ¥344m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-12-01 → 2024-11-30 | ¥404m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-11-30 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-11-30 | ¥378m |
| Pharmaceutical Productsreportable segment | employees | at 2025-11-30 | 154 pure |
| Real Estate Leasingreportable segment | employees | at 2025-11-30 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,479
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 28000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.023 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 25000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.021 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 25000 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.021 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 20000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.017 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 20000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.016 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 20000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.016 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 17000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.014 | |
| Number of shares held | CurrentYearInstant | 523000 | |
| Shareholding ratio | CurrentYearInstant | 0.429 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 2600 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 1213100 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 12131 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 4300 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 1220000 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 12131 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 2600 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 2600 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0021 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 2600 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 2600 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0021 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 73041000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 60.00 | |
| Number of male directors and other officers | FilingDateInstant | 8 | |
| Number of female directors and other officers | FilingDateInstant | 0 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000YamadaHideyukiMember | 14700 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000KayanoTakashiMember | 1700 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000IzumotoMasaruMember | 1100 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000AndouHiroyukiMember | 2500 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000HommaYoshitakaMember | 400 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000MiyamotoHiroshiMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000IshigamiNaohiroMember | 700 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000SuzukiShunsukeMember | － | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant | 21300 | |
| Audit fees reporting company | Prior1YearDuration | 15750000 | JPY |
| Non audit fees reporting company | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |